Presentation is loading. Please wait.

Presentation is loading. Please wait.

Lung Volume Measurements as a Surrogate Marker for Patient Response in Malignant Pleural Mesothelioma  Zacariah E. Labby, PhD, Samuel G. Armato, PhD,

Published byTeguh Iskandar Modified over 5 years ago

Similar presentations

Presentation on theme: "Lung Volume Measurements as a Surrogate Marker for Patient Response in Malignant Pleural Mesothelioma  Zacariah E. Labby, PhD, Samuel G. Armato, PhD,"— Presentation transcript:

1 Lung Volume Measurements as a Surrogate Marker for Patient Response in Malignant Pleural Mesothelioma  Zacariah E. Labby, PhD, Samuel G. Armato, PhD, James J. Dignam, PhD, Christopher Straus, MD, Hedy L. Kindler, MD, Anna K. Nowak, MD, PhD  Journal of Thoracic Oncology  Volume 8, Issue 4, Pages (April 2013) DOI: /JTO.0b013e c8 Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Kaplan–Meier survival curves for patients with and without normalized ipsilateral lung volume increase during the course of their therapy. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e c8) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Validation of automated lung segmentation. (A) Bland–Altman plot, where bias is shown with a solid black line and the 95% limits of agreement are shown with dashed black lines. (B) Direct comparison between measurements, with the identity line shown. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e c8) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Relative change from baseline of disease volumes versus relative change from baseline of linear-thickness measurements. The relationship expected from a spherical geometric model is indicated with a dashed black line. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e c8) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Relative change from baseline of disease volumes versus relative change from baseline of normalized ipsilateral lung volumes. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e c8) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

6 FIGURE 5 Relative changes from baseline scan of normalized ipsilateral lung volume and pleural disease volume for an example patient. Note the (anti-)correlation between the two curves. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e c8) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Lung Volume Measurements as a Surrogate Marker for Patient Response in Malignant Pleural Mesothelioma  Zacariah E. Labby, PhD, Samuel G. Armato, PhD,"

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,
Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB 150304  Martin J. Edelman, MD, Lydia.

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB   Martin J. Edelman, MD, Lydia.
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia  Arman Hasani, MBBS, FRACP, John M. Alvarez,

Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia  Arman Hasani, MBBS, FRACP, John M. Alvarez,
Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D
Combination of Mesothelin and CEA Significantly Improves the Differentiation between Malignant Pleural Mesothelioma, Benign Asbestos Disease, and Lung.

Combination of Mesothelin and CEA Significantly Improves the Differentiation between Malignant Pleural Mesothelioma, Benign Asbestos Disease, and Lung.
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma  Dean A. Fennell, PhD, FRCP,

Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma  Dean A. Fennell, PhD, FRCP,
Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis  Sarah Cargnin, PhD,
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis  Annemarie T. Fernandes, BA, Eric.

The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis  Annemarie T. Fernandes, BA, Eric.
Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 
Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.

Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.
Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases  Åslaug Helland, MD, PhD, Steinar Solberg,

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases  Åslaug Helland, MD, PhD, Steinar Solberg,

Similar presentations

Ads by Google